comparemela.com
Home
Live Updates
Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update : comparemela.com
Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Presented BDTX-1535 Phase 1 dose escalation data showing durable anti-tumor activity and favorable safety profile in NSCLC patients across heterogeneous EGFR mutations at the October 2023...
Related Keywords
Arizona
,
United States
,
Cambridge
,
Cambridgeshire
,
United Kingdom
,
Black Diamond
,
Phoenix
,
Mario Corso
,
Mark Velleca
,
Julie Seidel
,
Drug Administration
,
Nasdaq
,
Exchange Commission
,
Ivy Brain Tumor Center
,
Development Expenses
,
Company Masterkey
,
International Conference On Molecular
,
Diamond Therapeutics Inc
,
Molecular Targets
,
Diamond Therapeutics
,
Chief Executive Officer
,
Upcoming Milestones
,
Cancer Therapeutics
,
Board Mark Velleca
,
Chief Executive
,
Administrative Expenses
,
Private Securities Litigation Reform Act
,
Annual Report
,
United States Securities
,
Consolidated Balance Sheet Data
,
Investor Relations
,
Stern Investor
,
Markets
,
comparemela.com © 2020. All Rights Reserved.